Elagolix – GnRH Antagonist
GnRH is a peptide that stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function. Elagolix is a novel, orally administered gonadotropin-releasing hormone (GnRH) antagonist. Elagolix is believed to have its effect by altering the level of pituitary GnRH suppression and, as a result, titrating circulating hormone levels. By this method, it is believed that elagolix may provide relief from the pain associated with conditions such endometriosis and uterine fibroids, without a need to actively manage bone loss.
Elagolix is currently being investigated in both patients with endometriosis and those with uterine fibroids.
ELAGOLIX DEVELOPMENT: ABBVIE COLLABORATION
In June 2010, we announced an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation GnRH antagonists (collectively, GnRH Compounds) for women’s and men’s health. Under the terms of our agreement with AbbVie, we and AbbVie will work jointly to advance GnRH Compounds towards commercialization. Abbott made an upfront payment of $75 million and agreed to make additional development and regulatory event based payments of up to $480 million and up to an additional $50 million in commercial event based payments. Under the terms of the agreement, AbbVie is responsible for all development, marketing and commercialization costs. We will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.